论文部分内容阅读
心房颤动(AF)是最常见的严重心律失常。它的临床研究集中于心律失常的预防和血管事件及死亡的减少。2010年的重要进展在于用新抗凝剂和预防脑卒中、AF的处理。AF病人的处理中,考虑脑卒中预防至为重要。华法林预防AF病人的脑卒中有效,是预防脑卒中的基石,但它有药代动力学变异和需要复杂的监察等问题,又有不同程度的出血危险,所以采用率低。2009年,临床试验RE-LY以及随后美国和加
Atrial fibrillation (AF) is the most common severe arrhythmia. Its clinical studies have focused on the prevention of arrhythmias and the reduction of vascular events and deaths. Important progress in 2010 lies in the use of new anticoagulants and prevention of stroke, AF treatment. In the treatment of AF patients, consideration of stroke prevention is of the utmost importance. Warfarin is effective in preventing strokes in patients with AF and is the cornerstone of stroke prevention. However, it has pharmacokinetic variability and requires complicated monitoring. In addition, it has different degrees of bleeding risk, so the adoption rate is low. In 2009, the clinical trial RE-LY followed by the United States and Canada